Payment overview · 2025
General Payments
$11,900.91
188 reported records · 24 companies
Healthcare provider profile · identity verified
Dmitriy Grinshpun, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · BROOKLYN, NY · NPI 1265445639
Verified facts
What the public records show
CMS Open Payments records show Dmitriy Grinshpun, M.D. received $11,900.91 in general payments during 2025 across 188 reported records.
ABBVIE INC. accounted for 68.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Briviact, Gocovri, Ingrezza, Nourianz, Nuplazid, Nurtec Odt, Qulipta, Rexulti, Trintellix, Ubrelvy, Vraylar, Xcopri.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 344 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGENTYS as an associated drug or biological on 728 records involving 311 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ongentys by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rytary by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Auvelity by this doctor in 2024.
KYOWA KIRIN, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NOURIANZ as an associated drug or biological on 307 records involving 305 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Nourianz by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rexulti by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Gocovri by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xcopri by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Trintellix by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $8,119.01 | 68.2% | 48 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$555.09 | 4.7% | 17 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $500.41 | 4.2% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $461.11 | 3.9% | 16 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $382.21 | 3.2% | 14 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $279.96 | 2.4% | 12 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $179.01 | 1.5% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $166.74 | 1.4% | 8 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $153.01 | 1.3% | 7 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $150.12 | 1.3% | 7 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $149.74 | 1.3% | 7 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$120.40 | 1.0% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $103.72 | 0.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $92.85 | 0.8% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $86.58 | 0.7% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $85.19 | 0.7% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $76.04 | 0.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $52.25 | 0.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $49.54 | 0.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$32.00 | 0.3% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $31.91 | 0.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.58 | 0.2% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $26.92 | 0.2% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $19.52 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,925.00 | 5 |
| Food and Beverage | $4,969.11 | 182 |
| Education | $6.80 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $6,584.67 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $5,395.75 | 15 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $628.37 | 16 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $326.31 | 11 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $279.96 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $269.11 | 12 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $261.95 | 16 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $254.25 | 9 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $156.78 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $152.02 | 7 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $134.80 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $123.74 | 6 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $120.40 | 4 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $109.54 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $103.72 | 4 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $100.07 | 4 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $92.85 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $86.58 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $85.19 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $81.42 | 4 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $76.04 | 3 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $68.70 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $52.25 | 2 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $49.67 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $49.54 | 2 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $45.19 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.00 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $43.00 | 2 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $32.00 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $31.91 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| NOURIANZ Normalized: nourianz |
Drug | KYOWA KIRIN, INC. | $26.92 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $4.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gocovri gocovri |
2025 | Gocovri | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NOURIANZ nourianz |
2025 | Nourianz | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 261 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 59 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 181 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 344 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 102 | exact normalized | Medicare Part D |
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
261 | 58 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
344 | 51 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
102 | 21 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | ONGENTYS open payments reported associated product |
CMS Open Payments — General Payments 728 supporting records · 311 recipient NPIs · example record 1220525547 |
Ongentys · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| KYOWA KIRIN, INC. Exact reporting entity; no affiliate inference |
2025 | NOURIANZ open payments reported associated product |
CMS Open Payments — General Payments 307 supporting records · 305 recipient NPIs · example record 1222071383 |
Nourianz · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
148 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
181 | 38 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1205 | 206 |
| Baclofen | Baclofen | 1175 | 216 |
| Duloxetine Hcl | Duloxetine Hcl | 1088 | 174 |
| Mirtazapine | Mirtazapine | 1075 | 174 |
| Donepezil Hcl | Donepezil Hcl | 755 | 118 |
| Diclofenac Sodium | Diclofenac Sodium | 720 | 113 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 662 | 97 |
| Escitalopram Oxalate | Escitalopram Oxalate | 626 | 126 |
| Naproxen | Naproxen | 606 | 110 |
| Meloxicam | Meloxicam | 580 | 135 |
| Divalproex Sodium | Divalproex Sodium | 503 | 104 |
| Amitriptyline Hcl | Amitriptyline Hcl | 499 | 99 |
| Primidone | Primidone | 383 | 61 |
| Lamotrigine | Lamotrigine | 371 | 56 |
| Levetiracetam | Levetiracetam | 362 | 56 |
| Ubrelvy | Ubrogepant | 344 | 51 |
| Topiramate | Topiramate | 333 | 58 |
| Celecoxib | Celecoxib | 305 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 298 | 43 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 297 | 46 |
| Pregabalin | Pregabalin | 269 | 43 |
| Qulipta | Atogepant | 261 | 58 |
| Quetiapine Fumarate | Quetiapine Fumarate | 254 | 43 |
| Memantine Hcl | Memantine Hcl | 238 | 40 |
| Trazodone Hcl | Trazodone Hcl | 209 | 36 |
| Rivastigmine | Rivastigmine | 207 | 32 |
| Sumatriptan Succinate | Sumatriptan Succinate | 197 | 36 |
| Bupropion Xl | Bupropion Hcl | 189 | 31 |
| Propranolol Hcl Er | Propranolol Hcl | 181 | 35 |
| Trintellix | Vortioxetine Hydrobromide | 181 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 149 | 21 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 148 | 17 |
| Entacapone | Entacapone | 146 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 144 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 142 | 23 |
| Amantadine | Amantadine Hcl | 108 | 21 |
| Oxcarbazepine | Oxcarbazepine | 104 | 14 |
| Tramadol Hcl | Tramadol Hcl | 104 | 13 |
| Memantine Hcl Er | Memantine Hcl | 102 | 14 |
| Vraylar | Cariprazine Hcl | 102 | 21 |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 99 | 14 |
| Neupro | Rotigotine | 98 | 15 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 96 | 16 |
| Sertraline Hcl | Sertraline Hcl | 95 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 79 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 75 | 19 |
| Aripiprazole | Aripiprazole | 73 | suppressed |
| Lidocaine | Lidocaine | 73 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 20 |
| Meclizine Hcl | Meclizine Hcl | 66 | 20 |
| Belsomra | Suvorexant | 61 | 12 |
| Rexulti | Brexpiprazole | 59 | 15 |
| Rytary | Carbidopa/Levodopa | 59 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 57 | suppressed |
| Omeprazole | Omeprazole | 55 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 54 | 14 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 54 | suppressed |
| Ibuprofen | Ibuprofen | 53 | 13 |
| Olanzapine | Olanzapine | 51 | suppressed |
| Acetazolamide Er | Acetazolamide | 50 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 47 | suppressed |
| Acetazolamide | Acetazolamide | 46 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 45 | 11 |
| Risperidone | Risperidone | 45 | suppressed |
| Gocovri | Amantadine Hcl | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Ztlido | Lidocaine | 43 | 11 |
| Lyrica | Pregabalin | 41 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 41 | suppressed |
| Linzess | Linaclotide | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 33 | suppressed |
| Briviact | Brivaracetam | 33 | suppressed |
| Exelon | Rivastigmine | 33 | suppressed |
| Nourianz | Istradefylline | 32 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 28 | suppressed |
| Gralise | Gabapentin | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Lacosamide | Lacosamide | 25 | suppressed |
| Keppra | Levetiracetam | 24 | suppressed |
| Vimpat | Lacosamide | 24 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Trokendi Xr | Topiramate | 22 | suppressed |
| Xcopri | Cenobamate | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Dhivy | Carbidopa/Levodopa | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Trileptal | Oxcarbazepine | 20 | suppressed |
| Zolmitriptan | Zolmitriptan | 20 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Fycompa | Perampanel | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Ongentys | Opicapone | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 12 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 12 | suppressed |
| Keppra Xr | Levetiracetam | 12 | suppressed |
| Topiramate Er | Topiramate | 12 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $11,900.91 · 188 records | ABBVIE INC. | Auvelity, BOTOX, Briviact, CAPLYTA, CREXONT, ELIQUIS, FANAPT, Fintepla, Gocovri, INGREZZA, KESIMPTA, LEQEMBI, LOKELMA, NOURIANZ, NUPLAZID, NURTEC ODT, PAXLOVID, PERCEPT PC BRAINSENSE, PONVORY, QULIPTA, REXULTI, Rystiggo, SPRAVATO, Symbravo, TONMYA, TRINTELLIX, UBRELVY, UPLIZNA, VALTOCO, VRAYLAR, VUMERITY, VYEPTI, VYVGART HYTRULO, XCOPRI, ZAVZPRET | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error